Fidelity Management and Research Company
Corporate investor
Active
Boston, United States
392
276M
300
5.09
36
0.21
126
- Stages of investment
- Areas of investment
Summary
Fidelity Management and Research Company appeared to be the VC, which was created in 1946. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Boston.
Considering the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2018. Opposing the other organizations, this Fidelity Management and Research Company works on 12 percentage points more the average amount of lead investments. The typical startup value when the investment from Fidelity Management and Research Company is more than 1 billion dollars. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. The common things for fund are deals in the range of more than 100 millions dollars.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Fidelity Management and Research Company, startups are often financed by Atlas Venture, Venrock, The Column Group. The meaningful sponsors for the fund in investment in the same round are Invus, Wellington Management, Redmile Group. In the next rounds fund is usually obtained by ARCH Venture Partners, EcoR1 Capital, T. Rowe Price.
Among the most popular portfolio startups of the fund, we may highlight Lyft, Moderna Therapeutics, Magic Leap. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Pharmaceutical, Medical Device. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
The overall number of key employees were 2.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 392
- Lead investments
- 36
- Exits
- 126
- Rounds per year
- 5.09
- Follow on index
- 0.21
- Investments by industry
- Biotechnology (140)
- Health Care (100)
- Medical (66)
- Software (59)
- Therapeutics (51) Show 270 more
- Investments by region
-
- United States (316)
- Singapore (1)
- United Kingdom (12)
- India (7)
- Canada (14) Show 14 more
- Peak activity year
- 2021
- Number of Unicorns
- 79
- Number of Decacorns
- 96
- Number of Minotaurs
- 60
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 2B
- Group Appearance index
- 0.96
- Avg. company exit year
- 10
- Avg. multiplicator
- 1.86
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
AgomAb Therapeutics | 11 Oct 2023 | Biotechnology, Health Care, Therapeutics | Late Stage Venture | 111M | East Flanders, Ghent, Belgium |
Apogee Therapeutics | 07 Dec 2022 | Biotechnology, Medical, Life Science, Therapeutics | Early Stage Venture | 149M | United States, California, San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.